Research programme: hypoglycaemia therapy - Roche

Drug Profile

Research programme: hypoglycaemia therapy - Roche

Alternative Names: MAR-531

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Marcadia Biotech
  • Developer Roche
  • Class Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Hypoglycaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hypoglycaemia in USA (SC, Injection)
  • 30 Dec 2010 Marcadia Biotech has been acquired and merged into Roche
  • 28 Jun 2010 Marcadia Biotech and Eli Lilly enter into an exclusive development and licensing agreement for the former's glucagon analogue programme. Under the agreement, Eli Lilly is responsible for development outside the US, and for commercialisation worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top